View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 11, 2020

Abbott launches radiofrequency device for chronic pain patients

Abbott has announced the US launch of IonicRF Generator, a radiofrequency ablation device that uses heat to target specific nerves and prevent pain signals from reaching the brain.

Abbott has announced the US launch of IonicRF Generator, a radiofrequency ablation device that uses heat to target specific nerves and prevent pain signals from reaching the brain.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The device has been recently cleared by the Food and Drug Administration (FDA) to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system.

IonicRF Generator is currently approved in the US and Europe. It is the first radiofrequency ablation device developed by Abbott.

Radiofrequency ablation prevents the nerve tissue from sending pain signals by using an electric current to heat up a small area of the tissue.

In studies, it was found that pain relief, following a single radiofrequency ablation treatment, can last from six to 12 months.

Abbott Neuromodulation vice-president Keith Boettiger said: “Most people who are candidates for radiofrequency ablation have tried other therapies such as medications and injections with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication.

“We are proud to be able to provide the first Abbott-designed radiofrequency ablation device engineered to deliver safe and effective pain management. This is another example of our focus on widening the breadth of our neuromodulation portfolio and keeping patients central to everything we do at Abbott.”

Lower back pain is considered to be one of the most common medical complaints globally while facet joint syndrome, which is often treated by radiofrequency ablation therapy, accounts for 15% of these complaints.

Radiofrequency ablation has been used for the treatment of pain, including lower back pain and Sacroiliac joint pain, that failed to resolve with conservative treatments such as physical therapy, injections, or medication.

In July, Abbott’s iOS-compatible app for chronic pain patients received FDA approval.

In November 2018, Abbott introduced its DRG Invisible Trial System to help in chronic pain management.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network